Treatment and outcomes after LS
| Characteristics . | Patients with LS, n = 70 . | Patients who received therapy for LS, n = 65 . |
|---|---|---|
| First-line treatment approach | ||
| Chemotherapy + gemtuzumab | 14 (20%) | 14 (21.5%) |
| High-dose chemotherapy | 27 (38.6%) | 27 (41.5%) |
| Venetoclax/azacitidine | 6 (8.6%) | 6 (9.2%) |
| Low-dose chemotherapy | 12 (17.1%) | 12 (18.5%) |
| Other∗ | 4 (5.7%) | 4 (6.2%) |
| Palliative care | 2 (2.9%) | 2 (3.1%) |
| No therapy | 4 (5.7%) | --- |
| Unknown | 1 (1.4%) | --- |
| First-line treatment intent | ||
| Remission induction and/or bridge to HSCT | 54 (77.1%) | 54 (83.1%) |
| Hospice/palliative care | 9 (12.9%) | 9 (13.8%) |
| Unknown | 1 (1.4%) | --- |
| Other† | 2 (2.9%) | 2 (3.1%) |
| No treatment | 4 (5.7%) | --- |
| CR to first-line treatment‡ | 20 (28.6%) | 20 (30.8%) |
| CR at any point after LS diagnosis‡ | 23 (32.9%) | 23 (35.4%) |
| Regimen leading to CR (n = 23) | ||
| Chemotherapy + gemtuzumab | 7 (30.4%) | |
| High-dose chemotherapy | 7 (30.4%) | |
| Venetoclax/azacitidine | 3 (13%) | |
| Low-dose chemotherapy | 2 (8.7%) | |
| Other§ | 4 (17.4%) | |
| Median number of lines of therapy for LS excluding HSCT (range) | 1 (0-6) | |
| Consolidative HSCT after LS diagnosis | 14 (20%) | 14 (21.5%) |
| Reversion at any point to B-ALL | 7 (10%) | 7 (10.8%) |
| Outcomes|| (n = 69) | ||
| Death from LS | 52 (75.4%) | |
| Death from TRM in CR | 5 (7.2%) | |
| Death from other cause¶ | 4 (5.8%) | |
| Alive in CR | 6 (8.7%) | |
| Alive with LS | 1 (1.4%) | |
| Alive with B-ALL | 1 (1.4%) | |
| Characteristics . | Patients with LS, n = 70 . | Patients who received therapy for LS, n = 65 . |
|---|---|---|
| First-line treatment approach | ||
| Chemotherapy + gemtuzumab | 14 (20%) | 14 (21.5%) |
| High-dose chemotherapy | 27 (38.6%) | 27 (41.5%) |
| Venetoclax/azacitidine | 6 (8.6%) | 6 (9.2%) |
| Low-dose chemotherapy | 12 (17.1%) | 12 (18.5%) |
| Other∗ | 4 (5.7%) | 4 (6.2%) |
| Palliative care | 2 (2.9%) | 2 (3.1%) |
| No therapy | 4 (5.7%) | --- |
| Unknown | 1 (1.4%) | --- |
| First-line treatment intent | ||
| Remission induction and/or bridge to HSCT | 54 (77.1%) | 54 (83.1%) |
| Hospice/palliative care | 9 (12.9%) | 9 (13.8%) |
| Unknown | 1 (1.4%) | --- |
| Other† | 2 (2.9%) | 2 (3.1%) |
| No treatment | 4 (5.7%) | --- |
| CR to first-line treatment‡ | 20 (28.6%) | 20 (30.8%) |
| CR at any point after LS diagnosis‡ | 23 (32.9%) | 23 (35.4%) |
| Regimen leading to CR (n = 23) | ||
| Chemotherapy + gemtuzumab | 7 (30.4%) | |
| High-dose chemotherapy | 7 (30.4%) | |
| Venetoclax/azacitidine | 3 (13%) | |
| Low-dose chemotherapy | 2 (8.7%) | |
| Other§ | 4 (17.4%) | |
| Median number of lines of therapy for LS excluding HSCT (range) | 1 (0-6) | |
| Consolidative HSCT after LS diagnosis | 14 (20%) | 14 (21.5%) |
| Reversion at any point to B-ALL | 7 (10%) | 7 (10.8%) |
| Outcomes|| (n = 69) | ||
| Death from LS | 52 (75.4%) | |
| Death from TRM in CR | 5 (7.2%) | |
| Death from other cause¶ | 4 (5.8%) | |
| Alive in CR | 6 (8.7%) | |
| Alive with LS | 1 (1.4%) | |
| Alive with B-ALL | 1 (1.4%) | |
Four (6.1%) patients received “other” treatments including splenectomy for non-CNS EMD, daratumumab to target CD38 expression, B-ALL maintenance chemotherapy, and CNS-directed therapy including radiation.
Treatment intent not indicated; both patients received venetoclax-based combination therapy (eg, with azacitidine).
One patient lost to follow-up, 1 patient with unknown outcome after treatment, therefore n = 69.
“Other” CR inducing regimens include splenectomy for non-CNS EMD, B-ALL maintenance chemotherapy, CNS-directed therapy including radiation and inotuzumab.
One patient lost to follow-up, therefore n = 69.
Three patients died of TRM with disease, 1 died of B-ALL.